These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 27635438)

  • 1. 2-Methyl-6-(phenylethynyl)pyridine Hydrochloride Modulates Metabotropic Glutamate 5 Receptors Endogenously Expressed in Zebrafish Brain.
    Albasanz JL; Santana S; Guzman-Sanchez F; León D; Burgos JS; Martín M
    ACS Chem Neurosci; 2016 Dec; 7(12):1690-1697. PubMed ID: 27635438
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chronic oral administration of MPEP, an antagonist of mGlu
    López-Zapata A; León-Navarro DA; Crespo M; Albasanz JL; Martín M
    Neuroscience; 2017 Mar; 344():187-203. PubMed ID: 28012867
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chronic treatment with MPEP, an mGlu5 receptor antagonist, normalizes basal ganglia glutamate neurotransmission in L-DOPA-treated parkinsonian monkeys.
    Morin N; Morissette M; Grégoire L; Gomez-Mancilla B; Gasparini F; Di Paolo T
    Neuropharmacology; 2013 Oct; 73():216-31. PubMed ID: 23756168
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutational analysis and molecular modeling of the binding pocket of the metabotropic glutamate 5 receptor negative modulator 2-methyl-6-(phenylethynyl)-pyridine.
    Malherbe P; Kratochwil N; Zenner MT; Piussi J; Diener C; Kratzeisen C; Fischer C; Porter RH
    Mol Pharmacol; 2003 Oct; 64(4):823-32. PubMed ID: 14500738
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antagonism at metabotropic glutamate 5 receptors inhibits nicotine- and cocaine-taking behaviours and prevents nicotine-triggered relapse to nicotine-seeking.
    Tessari M; Pilla M; Andreoli M; Hutcheson DM; Heidbreder CA
    Eur J Pharmacol; 2004 Sep; 499(1-2):121-33. PubMed ID: 15363959
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 2-Methyl-6-(phenylethynyl)-pyridine (MPEP), a potent, selective and systemically active mGlu5 receptor antagonist.
    Gasparini F; Lingenhöhl K; Stoehr N; Flor PJ; Heinrich M; Vranesic I; Biollaz M; Allgeier H; Heckendorn R; Urwyler S; Varney MA; Johnson EC; Hess SD; Rao SP; Sacaan AI; Santori EM; Veliçelebi G; Kuhn R
    Neuropharmacology; 1999 Oct; 38(10):1493-503. PubMed ID: 10530811
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Functional Interaction Between NMDA and mGlu5 Receptors: Effects on Working Memory, Instrumental Learning, Motor Behaviors, and Dopamine Release.
    Homayoun H; Stefani MR; Adams BW; Tamagan GD; Moghaddam B
    Neuropsychopharmacology; 2004 Jul; 29(7):1259-69. PubMed ID: 15010696
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Compensatory molecular and functional mechanisms in nervous system of the Grm1(crv4) mouse lacking the mGlu1 receptor: a model for motor coordination deficits.
    Rossi PI; Musante I; Summa M; Pittaluga A; Emionite L; Ikehata M; Rastaldi MP; Ravazzolo R; Puliti A
    Cereb Cortex; 2013 Sep; 23(9):2179-89. PubMed ID: 22791805
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interactive effects of the mGlu5 receptor antagonist MPEP and the mGlu2/3 receptor antagonist LY341495 on nicotine self-administration and reward deficits associated with nicotine withdrawal in rats.
    Liechti ME; Markou A
    Eur J Pharmacol; 2007 Jan; 554(2-3):164-74. PubMed ID: 17113075
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [3H]Methoxymethyl-3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine binding to metabotropic glutamate receptor subtype 5 in rodent brain: in vitro and in vivo characterization.
    Anderson JJ; Rao SP; Rowe B; Giracello DR; Holtz G; Chapman DF; Tehrani L; Bradbury MJ; Cosford ND; Varney MA
    J Pharmacol Exp Ther; 2002 Dec; 303(3):1044-51. PubMed ID: 12438526
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MPEP Lowers Binge Drinking in Male and Female C57BL/6 Mice: Relationship with mGlu5/Homer2/Erk2 Signaling.
    Huang G; Thompson SL; Taylor JR
    Alcohol Clin Exp Res; 2021 Apr; 45(4):732-742. PubMed ID: 33587295
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MPEP, an mGlu5 receptor antagonist, reduces the development of L-DOPA-induced motor complications in de novo parkinsonian monkeys: biochemical correlates.
    Morin N; Grégoire L; Morissette M; Desrayaud S; Gomez-Mancilla B; Gasparini F; Di Paolo T
    Neuropharmacology; 2013 Mar; 66():355-64. PubMed ID: 22884464
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metabotropic glutamate 5 receptor antagonism is associated with antidepressant-like effects in mice.
    Li X; Need AB; Baez M; Witkin JM
    J Pharmacol Exp Ther; 2006 Oct; 319(1):254-9. PubMed ID: 16803860
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cocaine self-administration, extinction training and drug-induced relapse change metabotropic glutamate mGlu5 receptors expression: Evidence from radioligand binding and immunohistochemistry assays.
    Pomierny-Chamiolo L; Miszkiel J; Frankowska M; Bystrowska B; Filip M
    Brain Res; 2017 Jan; 1655():66-76. PubMed ID: 27871824
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prolonged administration of antidepressant drugs leads to increased binding of [(3)H]MPEP to mGlu5 receptors.
    Nowak G; Pomierny-Chamioło L; Siwek A; Niedzielska E; Pomierny B; Pałucha-Poniewiera A; Pilc A
    Neuropharmacology; 2014 Sep; 84():46-51. PubMed ID: 24796254
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interactions between metabotropic glutamate 5 and adenosine A2A receptors in normal and parkinsonian mice.
    Kachroo A; Orlando LR; Grandy DK; Chen JF; Young AB; Schwarzschild MA
    J Neurosci; 2005 Nov; 25(45):10414-9. PubMed ID: 16280580
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anticonvulsant activity of two metabotropic glutamate group I antagonists selective for the mGlu5 receptor: 2-methyl-6-(phenylethynyl)-pyridine (MPEP), and (E)-6-methyl-2-styryl-pyridine (SIB 1893).
    Chapman AG; Nanan K; Williams M; Meldrum BS
    Neuropharmacology; 2000 Jul; 39(9):1567-74. PubMed ID: 10854901
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessing the role of metabotropic glutamate receptor 5 in multiple nociceptive modalities.
    Zhu CZ; Wilson SG; Mikusa JP; Wismer CT; Gauvin DM; Lynch JJ; Wade CL; Decker MW; Honore P
    Eur J Pharmacol; 2004 Dec; 506(2):107-18. PubMed ID: 15588730
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A close structural analog of 2-methyl-6-(phenylethynyl)-pyridine acts as a neutral allosteric site ligand on metabotropic glutamate receptor subtype 5 and blocks the effects of multiple allosteric modulators.
    Rodriguez AL; Nong Y; Sekaran NK; Alagille D; Tamagnan GD; Conn PJ
    Mol Pharmacol; 2005 Dec; 68(6):1793-802. PubMed ID: 16155210
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term treatment with l-DOPA and an mGlu5 receptor antagonist prevents changes in brain basal ganglia dopamine receptors, their associated signaling proteins and neuropeptides in parkinsonian monkeys.
    Morin N; Jourdain VA; Morissette M; Grégoire L; Di Paolo T
    Neuropharmacology; 2014 Apr; 79():688-706. PubMed ID: 24456747
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.